Preparing Module 3 for a marketing authorisation application often raises practical questions. Who should own the dossier? When should writing begin? How much time is realistically needed? And why do challenges arise even when the required data is available?
While Module 3 requirements are well established, challenges often arise in practice. In many cases, the issue is not missing data, but how information, scientific justification and quality strategy come together into one coherent dossier.
Below, we answer some of the common practical questions that arise during Module 3 preparation and lifecycle management. See also our previous blog post on How to write a strong Module 3 for a marketing authorisation application.
Who “owns” Module 3?
There is no single correct answer, but clear ownership is important. Module 3 preparation is typically a joint effort between CMC, regulatory affairs (RA) and quality assurance (QA). If ownership is unclear, the dossier can easily become a set of individually well-written sections rather than one coherent quality story. The manufacturing description, specifications, analytical methods, validation data and stability conclusions may all be present – but the reader may still need to work too hard to understand how they fit together.
Rather than focusing on which function should lead, the more important question is whether one accountable owner has been clearly defined and understood across functions. So, before writing starts, agree who is responsible for the overall logic of the dossier – not only for collecting or compiling the sections.
Why do challenges arise even when data is available?
Often, the challenge is not missing data. More commonly, difficulties arise because information is not sufficiently aligned or scientifically justified across sections.
For example, development studies may be described, but their relevance to the final formulation, manufacturing process or specification limits may not be clear. Analytical methods may be validated, but the connection to the intended control strategy may remain implicit. Stability data may be available, but the justification for shelf life or storage conditions may not be sufficiently explained.
A strong Module 3 is therefore not only about data availability, but about interpretation, regulatory judgement and presenting one coherent quality story.
What makes a control strategy convincing?
One common challenge is that control strategy is not located in a single section. Instead, it is distributed throughout Module 3 across pharmaceutical development, manufacturing, process controls, material and drug product specifications and related justifications.
As a result, assessors often need to connect information across multiple sections. If development rationale, process controls and specifications are not fully aligned, the dossier can feel fragmented even when individual sections are well written.
The aim is not to repeat the same explanation in every section. The aim is to make sure the same scientific logic is visible across the dossier. A useful test is to ask: if someone reads the dossier without joining any project meetings, would they understand why these controls were selected and how they work together?
The good news is that in next generation eCTD structure, according to ICH M4Q(R2) Control strategy will have it’s own location (2.3.2 Overall Development and Overall Control Strategy) which allows for a clearer and more structured presentation of the control strategy.
What updates are often needed when a dossier developed for another region is used for an EU submission?
A dossier developed for another region may follow the CTD structure, but this does not automatically mean that the content is ready for an EU marketing authorisation application. Common update needs may relate to, for example:
- development rationale and equivalence in case of generics
- justification of specifications and acceptance criteria
- compliance with European Pharmacopoeia
- stability data, shelf-life justification and storage conditions
- GMP-related information and manufacturing site documentation
- terminology, regional references and commitments
Practical tip:
Before using a dossier developed for another region in the EU, perform an EU-focused Module 3 gap analysis. The aim is not only to check whether sections are populated, but to assess whether the content, justifications and control strategy are suitable for EU expectations.
What if guidelines change during writing?
Regulatory expectations continue to evolve and changes can happen especially in longer development projects.
Submissions are expected to reflect current requirements at the time of filing. This makes continuous monitoring important during dossier preparation. However, new or revised guidelines are seldom implemented with very short lead times. There is usually a consultation, adoption and implementation phase, giving companies time to assess what the change means for ongoing and planned submissions.
What is changing with ICH M4Q(R2)?
ICH M4Q(R2) is expected to influence how quality information is structured and assessed. In simplified terms:
- Module 2.3 is expected to play a stronger role in presenting the scientific rationale and quality story
- Module 3 may increasingly function as a structured repository of quality information
In practice, this means companies may increasingly move from simply “writing a dossier” towards structuring and managing quality knowledge more strategically.
Module 3 writing is a strategic activity that directly affects approval timelines, regulatory burden and the long-term value of a marketing authorisation.
Medfiles supports the preparation and maintenance of Module 3 as part of the full marketing authorisation dossier. Our CMC and regulatory experts help ensure that quality data, control strategy and the overall application are aligned and meet current regulatory expectations. In addition, Medfiles CMC performs gap analyses for existing Module 3 dossiers, helping to identify missing, outdated or misaligned content.
We work across the lifecycle, from early development and dossier preparation to updates and responses during assessment, helping to keep your documentation clear, consistent and maintainable – whether you need support for individual tasks or fully outsourced solutions.
Author: Eeva-Maija Walin, Senior Pharmaceutical Chemical Expert
Eeva-Maija Walin has worked at Medfiles since 2019 as a Senior Pharmaceutical Chemical (CMC) Expert. She holds an M.Sc. in Chemistry and has further broadened her expertise through studies in pharmacy and microbiology at open universities. Prior to joining Medfiles, Eeva-Maija worked for almost 20 years in various CMC expert roles within the pharmaceutical industry.
She has extensive experience in CMC documentation for new marketing authorisation applications and post-approval variations submitted to EU medicines authorities and the FDA. Her expertise includes preparation of quality summaries, evaluation of client documentation against regulatory requirements (gap analyses), and advising on GMP-related matters. At Medfiles, Eeva-Maija supports clients in a wide range of drug development and lifecycle management projects for both human and veterinary medicinal products, drawing on her strong background in pharmaceutical development, quality documentation and regulatory compliance.
